TNFSF11 and osteoporosis: Pharmacological therapies for osteoporosis such as bisphosphonates or anti-RANKL monoclonal neutralizing antibody (denosumab) introduce additional considerations in surgical dental treatment due to the potential risk for developing medication-related osteonecrosis of the jaw (ONJ).3